CN115297872B - 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 - Google Patents
含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 Download PDFInfo
- Publication number
- CN115297872B CN115297872B CN202180022422.7A CN202180022422A CN115297872B CN 115297872 B CN115297872 B CN 115297872B CN 202180022422 A CN202180022422 A CN 202180022422A CN 115297872 B CN115297872 B CN 115297872B
- Authority
- CN
- China
- Prior art keywords
- mitochondria
- composition
- cells
- chondrocytes
- degenerative arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 33
- 206010007710 Cartilage injury Diseases 0.000 title claims abstract description 22
- 230000002438 mitochondrial effect Effects 0.000 title description 13
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 90
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 30
- 230000032683 aging Effects 0.000 claims abstract description 20
- 230000008439 repair process Effects 0.000 claims abstract description 14
- 239000003102 growth factor Substances 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 230000036407 pain Effects 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000000845 cartilage Anatomy 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 75
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 description 55
- 102000047217 human NR4A3 Human genes 0.000 description 55
- 238000002474 experimental method Methods 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 22
- 210000001772 blood platelet Anatomy 0.000 description 21
- 210000002381 plasma Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 210000004623 platelet-rich plasma Anatomy 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000004898 mitochondrial function Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- NBAOBNBFGNQAEJ-UHFFFAOYSA-M tetramethylrhodamine ethyl ester perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 NBAOBNBFGNQAEJ-UHFFFAOYSA-M 0.000 description 7
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000001700 mitochondrial membrane Anatomy 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000032677 cell aging Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 3
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 241001093575 Alma Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- WTCBONOLBHEDIL-UHFFFAOYSA-M Sodium iodate Chemical compound [Na+].[O-]I(=O)=O WTCBONOLBHEDIL-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- -1 4- (trifluoromethyl) phenyl Chemical group 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000195634 Dunaliella Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000022888 negative regulation of membrane potential Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
本发明一个实施例提供包含线粒体的组合物，藉由对软骨提供线粒体，可通过改善软骨细胞中线粒体的功能以提升软骨细胞的修复能力并修复软骨细胞老化导致的软骨损伤，进而达到改善并治疗退化性关节炎的目的。
Description
技术领域
本发明是关于线粒体的用途及含有线粒体的组合物，尤其是关于线粒体用于制备修复软骨损伤或改善退化性关节炎的组合物的用途以及含有线粒体及高浓度血小板血浆的组合物。
背景技术
退化性关节炎是人类老化最常见的关节疾病，主要病变的地方在于骨头与骨头之间的关节接触面，也就是所谓的关节软骨。在退化性关节炎病患的X光照片中可观察到软骨受损、关节表面凹凸不平、关节腔变窄以及骨刺产生。退化性关节炎主要的症状包含疼痛、僵硬、肿胀、发炎或变形。传统的退化性关节炎治疗方式包含药物治疗、物理治疗、玻尿酸注射、置换人工关节等。
然而，除了人工关节置换手术外，其他疗法大都只能短暂缓解发炎与疼痛，无法有效改善或延缓病程的进展。因此，如何改善并治疗退化性关节炎为目前的研究目标。
发明内容
根据本发明一个实施例，通过对软骨提供线粒体以修复软骨损伤，进而改善并治疗退化性关节炎。
本发明一个实施例提供一种线粒体用于制备修复软骨损伤的组合物的用途。
本发明一个实施例提供一种线粒体用于制备改善退化性关节炎的组合物的用途。
本发明一个实施例提供一种组合物，包含线粒体及来自血液的生长因子。
本发明一个实施例提供包含线粒体的组合物，藉由对软骨提供线粒体，可通过改善软骨细胞中线粒体的功能以提升软骨细胞的修复能力并修复软骨细胞老化导致的软骨损伤，改善软骨损伤或退化性关节炎所造成的疼痛现象、发炎肿胀反应或僵硬现象，进而达到改善并治疗退化性关节炎的目的。
附图说明
图1为使用75μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的细胞存活率的图表。
图2为使用50μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的老化程度的图表。
图3为使用50μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的染色照片。
图4为使用50μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的线粒体膜电位分析图。
具体实施方式
于以下实施方式中详细叙述本发明的详细特征及优点，其内容足以使任何熟习相关技艺者了解本发明的技术内容并据以实施，且根据本说明书所揭露的内容、权利要求书及附图，任何熟习相关技艺者可容易理解本发明相关的目的及优点。以下实施例用于进一步详细说明本发明的观点，但非以任何观点限制本发明的范畴。
线粒体是细胞内进行氧化磷酸化反应及合成三磷酸腺苷(ATP)的场所，除了提供细胞正常代谢所需的能量外，还负责调控细胞内氧化压力处理、讯号传递等功能。与正常的软骨细胞相比，在损伤或老化的软骨细胞中线粒体的功能明显下降，具体表现在ATP产能效率下降、膜电位下降电子传递链的效率变差等。伴随着线粒体的功能下降，各项生物反应会开始衰退，亦即是软骨细胞开始老化，使软骨细胞逐渐无法维持正常的运作，进而出现发炎或关节炎的症状。因此，通过将健康的线粒体提供给软骨细胞，可改善软骨老化现象并提升软骨修复能力，进一步治疗退化性关节炎等老化引起的疾病。
本发明一个实施例提供用于修复软骨损伤或改善退化性关节炎的组合物，包含线粒体。在本实施例中，线粒体的浓度可为每毫升1微克至4000微克(μg/mL)，但不限于此。在另一实施例中，线粒体的浓度可为每毫升1微克至200微克。在又一实施例中，线粒体的浓度可为每毫升1微克至100微克。在再一实施例中，线粒体的浓度可为每毫升1微克至40微克。在其他实施例中，线粒体的浓度可为每毫升15微克至40微克。在本实施例中，线粒体的有效剂量可为每1平方厘米的关节腔7.9毫克至2.11克，但不限于此。在其他实施例中，线粒体的有效剂量可为每1平方厘米的关节腔7.9毫克至21.1毫克。
组合物中包含的线粒体可为外源性线粒体。外源性线粒体为取自不同于施用组合物者的细胞。施用组合物者与提供外源性线粒体者较优选为同属，更优选为同种。在其他实施例中，线粒体可为取自施用组合物者本身的细胞的自体线粒体。提供线粒体的细胞被取出后，可直接从细胞分离出线粒体或将细胞经体外培养增殖后再分离出线粒体。前述提供外源性线粒体或提供自体线粒体的细胞可为脂肪干细胞、单核细胞、胚胎干细胞、间质干细胞、造血干细胞、CD34+干细胞、骨髓干细胞等具有线粒体的细胞。
本实施例的组合物可通过口服、注射等方式给予关节。通过注射的方式将组合物给予关节时，为将组合物注入到关节腔中，使组合物在关节腔中与软骨细胞接触而进入软骨细胞中。
在另一实施例中，组合物进一步包含来自血液的生长因子。生长因子可来自高浓度血小板血浆(platelet-rich plasma，PRP)。生长因子可包含TGF-β1、PDGF-AA、PDGF-AB或PDGF-BB。于此所述的高浓度血小板血浆每毫升含有1×109个血小板以及多种生长因子，其中TGF-β1的浓度可为7767皮克/毫升(pg/ml)以上，PDGF-AA的浓度可为9.73皮克/毫升(pg/ml)以上，PDGF-AB的浓度可为10皮克/毫升(pg/ml)以上，PDGF-BB的浓度可为590皮克/毫升(pg/ml)以上。在该组合物中，线粒体与高浓度血小板血浆的比例可为每10微升的高浓度血小板血浆含有1微克至40微克的线粒体，即1微克∶10微升至40微克∶10微升，但不限于此。在其他实施例中，线粒体与高浓度血小板血浆的比例可为每10微升的高浓度血小板血浆含有15微克至40微克的线粒体，即15微克∶10微升至40微克∶10微升。在此组合物中，线粒体的浓度可为每毫升1000微克至4000微克(μg/mL)，但不限于此。在其他实施例中，线粒体的浓度可为每毫升1500微克至4000微克。在本实施例中，线粒体的有效剂量可为每1平方厘米的关节腔7.9毫克至2.11克，但不以此为限。在其他实施例中，线粒体的有效剂量可为每1平方厘米的关节腔7.9毫克至21.1毫克。
在其他实施例中，组合物可进一步包含药学上可接受的载体，药学上可接受的载体包含用于任何标准医疗产品或美容产品的载体，依据组合物的形式所述载体可为半固体或液体。举例而言，载体包含但不限于玻尿酸、明胶、乳化剂、水、生理盐水、缓冲盐水或乙醇等不影响线粒体活性的物质。
以下说明如何制备本发明实施例的组合物。
[线粒体萃取]
本发明实施例所使用的线粒体取自人类脂肪干细胞(adipose-derived stemcell，ADSC)。干细胞培养液包含Keratinocyte SFM 1X溶液(Gibco)、牛垂体提取物(bovinepituitary extract，BPE，Gibco)、重量百分浓度10％的胎牛血清(HyClone)。在培养皿中将人类脂肪干细胞培养至细胞数为1.5×108个细胞，以杜氏磷酸盐缓冲液(DPBS)冲洗细胞。接着，移除杜氏磷酸盐缓冲液后，加入细胞剥离用的胰蛋白酶(Trypsin)，在37℃下反应3分钟后，再加入干细胞培养液以终止反应。接着，将细胞冲洗下来后打散，以600g离心10分钟，移除上清液。接着，于细胞中加入80毫升的IBC-1缓冲液(225mM甘露醇、75mM蔗糖、0.1mMEDTA、30mM Tris-HCl pH 7.4)，在均质器中于冰上研磨15次。接着，以1000g离心15分钟，将上清液收集至另一离心管，再以9000g离心10分钟，移除上清液。所获得的沉淀物即为线粒体。在线粒体沉淀物中加入1.5毫升的IBC-2缓冲液(225mM甘露醇、75mM蔗糖、30mM Tris-HCl pH 7.4)及蛋白质分解酶抑制剂，并置于4℃下保存。
〔实验一，修复软骨细胞损伤〕
在本实验中，使用75μM的tBHP诱导人类软骨肉瘤细胞(SW-1353)出现损伤。通过阿尔玛蓝检测试剂来评估包含线粒体的组合物对人类软骨肉瘤细胞的损伤的修复效果，并以细胞存活率来表示。
人类软骨肉瘤细胞常被用于探讨软骨损伤的机理，是常见的软骨细胞评估模式。本实验使用人类软骨肉瘤细胞培养液在0％二氧化碳的环境下进行人类软骨肉瘤细胞的培养。人类软骨肉瘤细胞培养液包含90％Leibovitz’s L-15培养基、2mM L-麸酰胺酸及重量百分浓度10％的胎牛血清。
过氧化叔丁醇(tert-butyl hydroperoxide，tBHP)为一种有机过氧化物，常用作为诱导细胞氧化压力损伤、老化与细胞凋亡的物质。本实验使用tBHP作为诱导人类软骨肉瘤细胞老化或损伤的物质。
阿尔玛蓝(Alamar blue)是用于检测细胞活力的检测试剂。检测试剂盒内的刃天青(resazurin)是一种氧化还原指示剂，其为无毒、可穿透细胞膜且低荧光性的深蓝色染料。当刃天青进入健康的细胞中，会因活细胞体内的还原环境而被还原成粉红色且具高荧光性的试卤灵(resorufin)。可藉由测量试卤灵的光吸收值或荧光值来评估细胞的活力。试卤灵的光吸收值或荧光值愈高，表示细胞活力愈高。细胞活力愈高表示细胞愈健康、增生能力愈强。细胞增殖能力愈强，表示细胞量愈多。因此，本实验使用阿尔玛蓝作为评估细胞存活率及细胞增殖率的指标。
以下说明实验流程。首先，取培养代数为4至10代间的人类软骨肉瘤细胞进行实验。将人类软骨肉瘤细胞培养至体积为培养皿的八分满时，移除培养皿中的培养液并使用磷酸盐缓冲液(phosphate buffered saline，PBS)润洗细胞。接着，在培养皿中加入0.25％的胰蛋白酶并使胰蛋白酶在37℃下反应5分钟，再加入人类软骨肉瘤细胞培养液以终止胰蛋白酶的反应。接者，将培养皿中的人类软骨肉瘤细胞及人类软骨肉瘤细胞培养液移至离心管中，以每分钟转速1000(Revolutions Per Minute，rpm)离心5分钟后，移除上清液。接着，再加入新的人类软骨肉瘤细胞培养液至离心管中，进行细胞计数。接着，将人类软骨肉瘤细胞以每孔2×104个细胞的密度于盛有人类软骨肉瘤细胞培养液的24孔盘中培养16小时。接着，于24孔盘中加入tBHP，使人类软骨肉瘤细胞在含有浓度为75μM的tBHP的培养液中培养4小时。接着，将含有tBHP的人类软骨肉瘤细胞培养液移除，加入含有不同浓度线粒体的组合物的培养液，使人类软骨肉瘤细胞在含有不同线粒体浓度的组合物的培养液中培养20小时。孔盘中线粒体的浓度为1μg/mL、15μg/mL或40μg/mL。培养完成后，使用磷酸盐缓冲液清洗人类软骨肉瘤细胞，并将培养液更换为含有阿尔玛蓝的培养液，培养3小时。培养完成后，以OD530/595的波长量测荧光，计算人类软骨肉瘤细胞的细胞存活率。
人类软骨肉瘤细胞的细胞存活率的实验结果如表1及图1所示。图1为使用75μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的细胞存活率的图表。空白组为未经tBHP诱导损伤的人类软骨肉瘤细胞。对照组为经tBHP诱导损伤但未施以实施例的组合物的人类软骨肉瘤细胞。试验组为经tBHP诱导损伤且分别施以包含1μg/mL、15μg/mL或40μg/mL的线粒体的组合物处理的人类软骨肉瘤细胞。纵轴为相对于空白组的细胞数，以细胞存活率(％)表示。实验结果显示试验组的细胞存活率皆大于对照组的细胞存活率，且细胞存活率随着线粒体浓度增加而提升，表示实施例的含有线粒体的组合物确实可改善tBHP对软骨细胞造成的损伤及死亡。
〔表1〕
〔实验二，修复软骨细胞老化〕
在本实验中，使用50μM的tBHP诱导人类软骨肉瘤细胞老化。通过SA-β-gal试剂盒来评估包含线粒体的组合物对tBHP所造成的老化的修复效果，并以老化程度来表示。
在老化的细胞中，老化相关-β-半乳糖苷酶(Senescence-associated beta-galactosidase，SA-β-gal)会被过度表达，因此SA-β-gal可作为细胞衰老的标记之一。本实验使用SA-β-gal试剂盒(Senescenceβ-Galactosidase Staining Kit#9860，CellSignaling technology)来评估人类软骨肉瘤细胞的老化状态。
本实验的实验流程与上述实验一的实验流程大致相同。差异在于将人类软骨肉瘤细胞以每孔4×104个细胞的密度于盛有人类软骨肉瘤细胞培养液的12孔盘中培养16小时。接着，于12孔盘中加入tBHP，使人类软骨肉瘤细胞在含有浓度为50μM的tBHP的培养液中培养4小时。接着，将含有tBHP的人类软骨肉瘤细胞培养液移除，加入含有不同浓度线粒体的组合物的培养液，使人类软骨肉瘤细胞在含有不同线粒体浓度的组合物的培养液中培养20小时。孔盘中线粒体的浓度为1μg/mL、15μg/mL或40μg/mL。培养完成后，使用磷酸盐缓冲液清洗人类软骨肉瘤细胞，并使用SA-β-gal试剂盒进行细胞老化的评估。
人类软骨肉瘤细胞的老化程度的实验结果如表2、图2及图3所示。图2为使用50μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的老化程度的图表。图3为使用50μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的染色照片。空白组为未经tBHP诱导损伤的人类软骨肉瘤细胞。对照组为经tBHP诱导损伤但未施以实施例的组合物的人类软骨肉瘤细胞。试验组为经tBHP诱导损伤且分别施以包含1μg/mL、15μg/mL或40μg/mL的线粒体的组合物处理的人类软骨肉瘤细胞。纵轴为老化程度(％)，老化程度为老化的细胞数占所有的细胞数的百分比。###表示相较于对照组具有显著差异(P＜0.01)。实验结果显示试验组的老化程度皆小于对照组的老化程度，且细胞老化程度随着线粒体浓度增加而降低，表示实施例的含有线粒体的组合物确实可改善tBHP对软骨细胞造成的老化。
〔表2〕
〔实验三，改善软骨细胞的线粒体功能〕
在本实验中，使用50μM的tBHP诱导人类软骨肉瘤细胞老化，并通过线粒体的膜电位来评估人类软骨肉瘤细胞中线粒体的功能。
线粒体功能分析系通过测量线粒体的膜电位改变来判断线粒体功能的好坏。TMRE(tetramethylrhodamine ethyl ester)是一种带正电的荧光染剂，会聚集在具有活性的线粒体上，故可使用TMRE来标记健康的线粒体。当线粒体活性较低或呈现去极化现象时线粒体的膜电位会降低，造成TMRE无法保留于线粒体上。FCCP(Carbonylcyanide 4-(trifluoromethoxy)phenylhydrazone)为可跨越线粒体内膜的离子载体，会与质子结合来破坏ATP的合成造成膜电位改变。FCCP可用来消除线粒体的膜电位，因此常被用于线粒体去活性或去极化的对照组。藉由TMRE与FCCP染色处理，分析荧光强度以得知线粒体的膜电位变化，以此作为判断线粒体功能的依据。通过流式细胞仪检测以TMRE处理后的上清液，可根据TMRE标记分析有功能的线粒体占上清液中所有粒子的比例。
本实验的实验流程与上述实验一的实验流程大致相同。差异在于将人类软骨肉瘤细胞以每孔1×105个细胞的密度于盛有人类软骨肉瘤细胞培养液的6孔盘中培养16小时。接着，于6孔盘中加入tBHP，使人类软骨肉瘤细胞在含有浓度为50μM的tBHP的培养液中培养4小时。接着，将含有tBHP的人类软骨肉瘤细胞培养液移除，加入含有不同浓度线粒体的组合物的培养液，使人类软骨肉瘤细胞在含有不同线粒体浓度的组合物的培养液中培养20小时。孔盘中线粒体的浓度为1μg/mL、15μg/mL或40μg/mL。培养完成后，使用磷酸盐缓冲液清洗人类软骨肉瘤细胞，并使用TMRE与FCCP进行染色处理，以流式细胞仪进行检测。
人类软骨肉瘤细胞的膜电位分析的实验结果如表3及图4所示。图4为使用50μM的tBHP处理再以实施例的组合物修复的人类软骨肉瘤细胞的线粒体膜电位分析图。空白组为未经tBHP诱导损伤的人类软骨肉瘤细胞。对照组为经tBHP诱导损伤但未施以实施例的组合物的人类软骨肉瘤细胞。试验组为经tBHP诱导损伤且分别施以包含1μg/mL、15μg/mL或40μg/mL的线粒体的组合物处理的人类软骨肉瘤细胞。实验结果显示，相较于对照组，试验组的具有功能的线粒体的数量较多，且恢复程度随着组合物中线粒体浓度增加而更接近空白组，表示实施例的含有线粒体的组合物确实可改善软骨细胞的线粒体功能，线粒体功能提升进一步表示细胞具有较佳的抗老化及修复能力。
〔表3〕
〔实验四，改善退化性关节炎〕
在本实验中，使用碘乙酸单钠(monosodium iodoacetate，MIA)诱导小鼠产生退化性关节炎，并通过旋转轮测试(rotarod analysis)评估包含线粒体的组合物以及包含线粒体及高浓度血小板血浆的组合物对退化性关节炎小鼠的运动能力的修复效果。本实验使用八周龄、体重约18至22克的C57BL/6雄性小鼠作为实验对象。
碘乙酸单钠(monosodium iodoacetate，MIA)为3-磷酸甘油醛脱氢酶(Glyceraldehyde 3-phosphate dehydrogenase)的活性抑制剂，可诱导出与人类骨关节炎(Osteoarthritis，OA)症状极为相似的软骨损伤，使软骨失去蛋白聚糖基质并诱导软骨细胞死亡。本实验使用MIA作为诱导退化性关节炎的物质。
旋转轮测试(rotarod analysis)为评估小鼠的平衡与协调能力的分析方式。在测试前一周，将小鼠放至旋转轮上训练，使小鼠能在旋转轮上的时间超过三分钟，进行实验处理后，再藉由小鼠在旋转轮上的时间评估小鼠的运动能力。
高浓度血小板血浆(platelet-rich plasma，PRP)为全血经离心后移除红血球成为富含血小板的血浆蛋白浓缩液。高浓度血小板血浆含有丰富的生长因子，因此被认为对软骨、肌腱、韧带等的修复有所帮助。本实验的高浓度血小板血浆来自Sprague-Dawley(SD)大鼠。首先以3％戊巴比妥钠(pentobarbital sodium)麻醉大鼠，剂量为每千克30毫克。接着，以含有柠檬酸右旋糖(acid citrate dextrose)抗凝剂的针筒对大鼠抽取全血约7至8毫升，其中血小板的浓度约为每毫升0.5×109至1.5x109个。将血液转移至15毫升离心管在室温下以150g进行第一次离心10分钟，将血小板及血浆收集至另一15毫升离心管在室温下以1500g进行第二次离心10分钟，第二次离心后移除四分之三的上清液，剩下的四分之一即为本实验所使用的高浓度血小板血浆。于此所述的高浓度血小板血浆每毫升含有1×109个血小板以及多种生长因子，所包含的生长因子的种类及浓度如下：TGF-β1(≥7767pg/ml)、PDGF-AA(≥9.73pg/ml)、PDGF-AB(≥10pg/ml)及PDGF-BB(≥590pg/ml)。
以下说明实验流程。首先，将小鼠分笼并给予数天适应期，避免小鼠因环境不适造成紧张焦虑而影响实验结果。注射MIA前先对小鼠进行旋转轮测试，作为第0天的数据并作为后续比较的基准。进行手术前10分钟给予小鼠0.25毫升的4％水合氯醛(cholrahydrate)。在手术途中，给予异氟醚(isoflurane)以维持麻醉避免小鼠苏醒。将0.1毫克MIA溶解于10微升的生理盐水中，使用30G(gauge)的针头注入小鼠的关节腔。在注射MIA后的第7天，以同样的注射方式将实施例的组合物注入小鼠的关节腔，并在第7、14天进行旋转轮测试，每次测试最长为1200秒钟，转速为20rpm。
小鼠的运动能力的实验结果如表4所示。对照组为经MIA诱导退化性关节炎但未施以实施例的组合物的小鼠。PRP组为经MIA诱导退化性关节炎且施以高浓度血小板血浆的小鼠。试验组为经MIA诱导退化性关节炎且分别施以包含不同浓度的线粒体及/或10微升的高浓度血小板血浆的组合物处理的小鼠。实验结果显示，相较于第0天尚未受退化性关节炎影响，在第7天时各组别的小鼠的运动能力下降至30％至40％。在第14天时，对照组仅恢复至40％，而PRP组及试验组的小鼠的运动能力皆恢复至50％以上。此外，相较于PRP组(10微升的高浓度血小板血浆)及实施例四(15μg的线粒体)，施以实施例六的组合物(15μg的线粒体及10μL的高浓度血小板血浆)的小鼠的运动能力明显提升。小鼠运动能力的恢复表示软骨损伤或退化性关节炎所造成的疼痛现象、发炎肿胀反应或僵硬现象受到舒缓及改善。由上述结果可知含有线粒体的组合物可改善患有退化性关节炎的动物的运动能力，且随着线粒体浓度提高可具有较佳的效果。此外，含有线粒体及高浓度血小板血浆的组合物相较于仅含有线粒体或仅含有高浓度血小板血浆的组合物可具有更优异的改善效果。
文献记载小鼠关节腔中软骨组织的面积约为1896.91平方微米。本实验证实对小鼠的关节腔给予15微克至40微克的线粒体，可有效改善软骨损伤或退化性关节炎所造成的疼痛现象、发炎肿胀反应或僵硬现象，因此，经换算，线粒体的有效剂量可为每1平方厘米的软骨组织7.9毫克至2.11克，较佳为每1平方厘米的软骨组织7.9毫克至21.1毫克。
〔表4〕
本发明一个实施例提供包含线粒体的组合物，藉由对软骨提供线粒体，可通过改善软骨细胞中线粒体的功能以提升软骨细胞的修复能力并修复软骨细胞老化导致的软骨损伤，改善软骨损伤或退化性关节炎所造成的疼痛现象、发炎肿胀反应或僵硬现象，进而达到改善并治疗退化性关节炎的目的。
Claims (10)
1.线粒体用于制备修复软骨损伤的组合物的用途，其中，所述组合物中的线粒体的浓度为每毫升1微克至4000微克（μg/mL）。
2.线粒体用于制备改善退化性关节炎的组合物的用途，其中，所述组合物中的线粒体的浓度为每毫升1微克至4000微克（μg/mL）。
3.如权利要求1所述的用途，其中，修复软骨损伤为修复软骨细胞老化导致的软骨损伤。
4.如权利要求1所述的用途，其中，修复软骨损伤为通过改善软骨细胞中线粒体的功能以提升软骨细胞的修复能力。
5.如权利要求1所述的用途，其中，所述组合物改善软骨损伤所造成的疼痛现象或发炎肿胀反应。
6.如权利要求2所述的用途，其中，改善退化性关节炎为修复因关节处的软骨细胞老化导致的软骨损伤。
7.如权利要求2所述的用途，其中，改善退化性关节炎为通过改善关节处的软骨细胞中线粒体的功能以提升关节处的软骨细胞的修复能力。
8.如权利要求2所述的用途，其中，所述组合物改善退化性关节炎所造成的疼痛现象或发炎肿胀反应。
9.如权利要求1或2所述的用途，其中，所述组合物进一步包含高浓度血小板血浆。
10.一种组合物，包含线粒体及来自血液的生长因子，其中，所述生长因子来自高浓度血小板血浆，且每10微升的高浓度血小板血浆含有1微克至40微克的线粒体。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992546P | 2020-03-20 | 2020-03-20 | |
| US62/992,546 | 2020-03-20 | ||
| PCT/CN2021/082094 WO2021185376A1 (zh) | 2020-03-20 | 2021-03-22 | 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115297872A CN115297872A (zh) | 2022-11-04 |
| CN115297872B true CN115297872B (zh) | 2024-03-29 |
Family
ID=77768010
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180022924.XA Pending CN115335065A (zh) | 2020-03-20 | 2021-03-19 | 细胞培养组合物及其用途 |
| CN202180014670.7A Active CN115135328B (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202311570784.7A Pending CN117357559A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202180014777.1A Active CN115103683B (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途 |
| CN202311621466.9A Pending CN117379458A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202180022422.7A Active CN115297872B (zh) | 2020-03-20 | 2021-03-22 | 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 |
| CN202180022370.3A Pending CN115315248A (zh) | 2020-03-20 | 2021-03-22 | 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180022924.XA Pending CN115335065A (zh) | 2020-03-20 | 2021-03-19 | 细胞培养组合物及其用途 |
| CN202180014670.7A Active CN115135328B (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202311570784.7A Pending CN117357559A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202180014777.1A Active CN115103683B (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途 |
| CN202311621466.9A Pending CN117379458A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180022370.3A Pending CN115315248A (zh) | 2020-03-20 | 2021-03-22 | 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20230165899A1 (zh) |
| EP (2) | EP4122474A4 (zh) |
| JP (1) | JP2023518083A (zh) |
| CN (7) | CN115335065A (zh) |
| TW (9) | TWI787761B (zh) |
| WO (6) | WO2021185340A1 (zh) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1914336A (zh) * | 2004-02-02 | 2007-02-14 | 雀巢技术公司 | 犬骨关节炎相关基因及相关的方法和组合物 |
| WO2013035101A1 (en) * | 2011-09-11 | 2013-03-14 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| CN104546915A (zh) * | 2015-02-16 | 2015-04-29 | 黑龙江天晴干细胞股份有限公司 | 一种治疗骨性关节炎的组合物、其制备方法及其应用 |
| CN105520891A (zh) * | 2014-09-30 | 2016-04-27 | 李德财 | 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法 |
| CN106822183A (zh) * | 2016-12-26 | 2017-06-13 | 上海斯能得医疗科技有限公司 | 一种光敏富血小板血浆凝胶及其制备方法和用途 |
| CN110022884A (zh) * | 2016-11-30 | 2019-07-16 | 白雁生物技术公司 | 含有线粒体的药物组合物 |
| CN110055216A (zh) * | 2019-05-09 | 2019-07-26 | 张秀明 | 一种改善间质干细胞生物学功能的方法 |
| WO2019151840A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 파이안바이오테크놀로지 | 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물 |
| CN110812480A (zh) * | 2019-11-28 | 2020-02-21 | 中国科学院昆明动物研究所 | 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用 |
| CN112154210A (zh) * | 2018-03-13 | 2020-12-29 | 利兰斯坦福初级大学董事会 | 用于逆转细胞老化的瞬时细胞重编程 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005274B1 (en) * | 1999-09-15 | 2006-02-28 | Migenix Corp. | Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
| EP2591812A1 (en) * | 2011-11-14 | 2013-05-15 | University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) | A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair |
| US20140024677A1 (en) * | 2012-04-09 | 2014-01-23 | Musc Foundation For Research Development | Methods for inducing mitochondrial biogenesis |
| WO2013171752A1 (en) * | 2012-05-16 | 2013-11-21 | Minovia Therapeutics Ltd. | Compositions and methods for inducing angiogenesis |
| CN105163750B (zh) * | 2013-02-07 | 2022-07-15 | 李震义 | 长效人重组可溶性肿瘤坏死因子α受体在制备预防和治疗慢性肝病重症肝损伤药物中的用途 |
| US20150064715A1 (en) * | 2013-08-28 | 2015-03-05 | Musc Foundation For Research Development | Urinary biomarkers of renal and mitochondrial dysfunction |
| TWI672147B (zh) * | 2014-09-10 | 2019-09-21 | 台灣粒線體應用技術股份有限公司 | 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法 |
| JP6355220B2 (ja) * | 2014-12-31 | 2018-07-11 | 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． | 肺損傷を治療するための新規な医薬組成物及びその使用 |
| IL299482A (en) * | 2015-02-26 | 2023-02-01 | Minovia Therapeutics Ltd | Mammalian cells are enriched in active mitochondria |
| CN105030647B (zh) * | 2015-09-14 | 2018-04-24 | 广州赛莱拉干细胞科技股份有限公司 | 一种减少皱纹的制剂及其制备方法 |
| JP7185527B2 (ja) * | 2016-01-15 | 2022-12-07 | ザ チルドレンズ メディカル センター コーポレーション | ミトコンドリアおよび組み合わされたミトコンドリア剤の治療的使用 |
| US20170224764A1 (en) * | 2016-02-10 | 2017-08-10 | Cornell University | Therapeutic targeting of mitochondria to prevent osteoarthritis |
| TWI637748B (zh) * | 2016-07-12 | 2018-10-11 | 中山醫學大學 | 蓮蓬萃取物用於治療及／或預防腎臟病變之用途 |
| CN106190963A (zh) * | 2016-07-13 | 2016-12-07 | 浙江大学 | 一种采用线粒体移植促进损伤神经元存活的方法 |
| EP3600351A4 (en) * | 2017-03-26 | 2020-11-25 | Minovia Therapeutics Ltd. | MITOCHONDRIAL COMPOSITIONS AND PROCESSES FOR THE TREATMENT OF THE SKIN AND HAIR |
| EP3630134B8 (en) * | 2017-06-01 | 2022-01-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Formation of stable cartilage |
| CN107625969A (zh) * | 2017-10-18 | 2018-01-26 | 南京市儿童医院 | MiR‑214拮抗剂在制备用于减轻蛋白尿引起的肾小管损伤相关病症的药物中的用途 |
| WO2019083201A2 (ko) * | 2017-10-24 | 2019-05-02 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도 |
| KR20190052266A (ko) * | 2017-11-08 | 2019-05-16 | 원광대학교산학협력단 | 우르솔산을 유효성분으로 포함하는 신장 기능의 개선 또는 치료용 조성물 |
| WO2019183042A1 (en) * | 2018-03-20 | 2019-09-26 | Unity Biotechnology, Inc. | Autologous mitochondrial extraction and expansion |
| EP3823645A4 (en) * | 2018-07-22 | 2022-04-13 | Minovia Therapeutics Ltd. | MITOCHONDRIAL AUGMENTATION THERAPY OF KIDNEY DISEASES |
| KR20210035829A (ko) * | 2018-07-22 | 2021-04-01 | 미노비아 테라퓨틱스 리미티드 | 기능성 미토콘드리아가 풍부화된 줄기 세포를 사용한 미토콘드리아 증강 요법 |
| KR102128003B1 (ko) * | 2018-10-31 | 2020-06-29 | 차의과학대학교 산학협력단 | 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물 |
| CN110638833A (zh) * | 2019-11-15 | 2020-01-03 | 西安圣德生物科技有限公司 | 促进毛发生长的组合物及其使用方法 |
-
2021
- 2021-03-18 TW TW110109765A patent/TWI787761B/zh active
- 2021-03-18 TW TW112139490A patent/TW202404618A/zh unknown
- 2021-03-18 TW TW110109766A patent/TWI789723B/zh active
- 2021-03-18 TW TW111140519A patent/TWI827321B/zh active
- 2021-03-18 TW TW110109767A patent/TWI789724B/zh active
- 2021-03-19 TW TW111141019A patent/TW202308668A/zh unknown
- 2021-03-19 US US17/912,458 patent/US20230165899A1/en active Pending
- 2021-03-19 CN CN202180022924.XA patent/CN115335065A/zh active Pending
- 2021-03-19 CN CN202180014670.7A patent/CN115135328B/zh active Active
- 2021-03-19 US US17/912,394 patent/US20230137870A1/en active Pending
- 2021-03-19 EP EP21770630.8A patent/EP4122474A4/en active Pending
- 2021-03-19 WO PCT/CN2021/081685 patent/WO2021185340A1/zh active Application Filing
- 2021-03-19 TW TW110109872A patent/TW202135779A/zh unknown
- 2021-03-19 WO PCT/CN2021/081687 patent/WO2021185342A1/zh active Application Filing
- 2021-03-19 CN CN202311570784.7A patent/CN117357559A/zh active Pending
- 2021-03-19 JP JP2022556517A patent/JP2023518083A/ja active Pending
- 2021-03-19 CN CN202180014777.1A patent/CN115103683B/zh active Active
- 2021-03-19 TW TW110109874A patent/TWI796653B/zh active
- 2021-03-19 TW TW110109873A patent/TWI787763B/zh active
- 2021-03-19 WO PCT/CN2021/081686 patent/WO2021185341A1/zh active Application Filing
- 2021-03-19 CN CN202311621466.9A patent/CN117379458A/zh active Pending
- 2021-03-19 US US17/912,336 patent/US20230042445A1/en active Pending
- 2021-03-19 WO PCT/CN2021/081854 patent/WO2021185364A1/zh active Application Filing
- 2021-03-22 WO PCT/CN2021/082117 patent/WO2021185377A1/zh active Application Filing
- 2021-03-22 EP EP21770632.4A patent/EP4122444A4/en active Pending
- 2021-03-22 WO PCT/CN2021/082094 patent/WO2021185376A1/zh active Application Filing
- 2021-03-22 CN CN202180022422.7A patent/CN115297872B/zh active Active
- 2021-03-22 CN CN202180022370.3A patent/CN115315248A/zh active Pending
-
2022
- 2022-09-19 US US17/948,007 patent/US20230023438A1/en active Pending
- 2022-09-19 US US17/947,994 patent/US20230023218A1/en active Pending
- 2022-09-20 US US17/948,764 patent/US20230016499A1/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1914336A (zh) * | 2004-02-02 | 2007-02-14 | 雀巢技术公司 | 犬骨关节炎相关基因及相关的方法和组合物 |
| WO2013035101A1 (en) * | 2011-09-11 | 2013-03-14 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| CN105520891A (zh) * | 2014-09-30 | 2016-04-27 | 李德财 | 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法 |
| CN104546915A (zh) * | 2015-02-16 | 2015-04-29 | 黑龙江天晴干细胞股份有限公司 | 一种治疗骨性关节炎的组合物、其制备方法及其应用 |
| CN110022884A (zh) * | 2016-11-30 | 2019-07-16 | 白雁生物技术公司 | 含有线粒体的药物组合物 |
| CN106822183A (zh) * | 2016-12-26 | 2017-06-13 | 上海斯能得医疗科技有限公司 | 一种光敏富血小板血浆凝胶及其制备方法和用途 |
| WO2019151840A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 파이안바이오테크놀로지 | 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물 |
| CN112154210A (zh) * | 2018-03-13 | 2020-12-29 | 利兰斯坦福初级大学董事会 | 用于逆转细胞老化的瞬时细胞重编程 |
| CN110055216A (zh) * | 2019-05-09 | 2019-07-26 | 张秀明 | 一种改善间质干细胞生物学功能的方法 |
| CN110812480A (zh) * | 2019-11-28 | 2020-02-21 | 中国科学院昆明动物研究所 | 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用 |
Non-Patent Citations (4)
| Title |
|---|
| Blanco FJ等.The role of mitochondria in osteoarthritis.《Nat Rev Rheumatol》.2011,第7卷(第3期),第161-169页. * |
| Tang Q等.Trehalose ameliorates oxidative stress-mediated mitochondrial dysfunction and ER stress via selective autophagy stimulation and autophagic flux restoration in osteoarthritis development..《Cell Death Dis》.2017,第8卷(第10期),第1-14页. * |
| 周明等.自体去白细胞富血小板血浆治疗膝骨关节炎的早期临床疗效观察.《解放军医学院学报》.2019,第40卷(第8期),第757-763页. * |
| 自体去白细胞富血小板血浆治疗膝骨关节炎的早期临床疗效观察;周明等;《解放军医学院学报》;第40卷(第8期);第 757-763 页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Bone marrow mesenchymal stem cell-derived exosomes prevent osteoarthritis by regulating synovial macrophage polarization | |
| US20210260129A1 (en) | Cell Expansion Methods and Therapeutic Compositions | |
| CN106916783B (zh) | 肌肉干细胞体外培养方法及其应用 | |
| Lv et al. | Adipose‐derived stem cells regulate metabolic homeostasis and delay aging by promoting mitophagy | |
| Fu et al. | Beneficial effect of human umbilical cord‑derived mesenchymal stem cells on an endotoxin‑induced rat model of preeclampsia | |
| CN113136362B (zh) | 一种囊泡及其应用 | |
| JP2021531284A (ja) | 原発性ミトコンドリア病のためのミトコンドリア増強療法 | |
| Zayed et al. | Donor-matched comparison of chondrogenic potential of equine bone marrow-and synovial fluid-derived mesenchymal stem cells: implications for cartilage tissue regeneration | |
| JP2022519409A (ja) | 機能的ミトコンドリアで富化された幹細胞を用いたミトコンドリア増強療法 | |
| JP2021531288A (ja) | 眼疾患のミトコンドリア増強療法 | |
| JP2021532091A (ja) | 膵臓疾患のミトコンドリア増強療法 | |
| JP2021532095A (ja) | 肝臓疾患のミトコンドリア増強療法 | |
| Chan et al. | Safety study of allogeneic mesenchymal stem cell therapy in animal model | |
| CN113134014B (zh) | 囊泡在制备血友病药物中的应用 | |
| CN116474000B (zh) | 脐带间充质干细胞制剂、制备方法及其在治疗膝骨关节炎中的应用 | |
| CN115297872B (zh) | 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 | |
| Nicpoń et al. | The advantages of autologus adipose derived mesenchymal stem cells (AdMSCs) over the non-steroidal anti-inflammatory drugs (NSAIDs) application for degenerative elbow joint disease treatment in dogs-twelve cases. | |
| Liu et al. | Conditioned medium from human dental pulp stem cells treats spinal cord injury by inhibiting microglial pyroptosis | |
| TW202319536A (zh) | 用於治療慢性腎病之間葉幹細胞 | |
| TWI780431B (zh) | 新穎性醫藥組合物及其於修復肝臟損傷、治療肝臟損傷相關疾病與提升肝臟功能之用途 | |
| CN111514164A (zh) | 一种用于肺病治疗的脂肪间充质干细胞及其制备方法 | |
| Soltero-Rivera et al. | Distinctive characteristics of extracellular vesicles from feline adipose and placenta stromal cells unveil potential for regenerative medicine in cats | |
| Fujiwara et al. | Effect of platelet lysate on Schwann-like cell differentiation of equine bone marrow-derived mesenchymal stem cells | |
| TWI759739B (zh) | 新穎性醫藥組合物於修復視網膜損傷與治療視網膜病變之用途 | |
| CN114504595B (zh) | 尿液中的cd24阳性表达细胞及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |